Mike Exton, Managing Director at Novartis Taiwan, describes the affiliate’s plans to increase collaboration with the government in order to provide Taiwanese patients with a greater access to innovative, life-changing products, while highlighting Novartis’ world-class innovation in many critical therapeutic areas, such as heart failure, as well as the skilled Taiwanese talent pool that contributes to make Novartis Taiwan one of the most commercially efficient affiliates of the group.
You became Managing Director in August 2015. What has been some of the main challenges you faced when taking over the helm of the Taiwanese affiliate?
"It is the same for all MDs: you are informed your next posting will be Taiwan and you just go."
